Johnson, Felix
Stenzl, Anna
Hofauer, Benedikt
Heppt, Helen
Ebert, Eva-Vanessa
Wollenberg, Barbara
Lochbaum, Robin
Hahn, Janina
Greve, Jens
Trainotti, Susanne
Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Accepted: 8 October 2023
First Online: 2 November 2023
Declarations
:
: No financial assistance from any pharmaceutical company was obtained for this study. The authors of this study declare the following conflict of interests: F. Johnson: has received grant research support and/or speaker/consultancy fees from CSL Behring, Takeda and Pharming. He has also received funding to attend conferences/educational events from CSL Behring, Takeda and Pharming. He has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, IONIS Pharmaceuticals and Takeda. A. Stenzl: has no conflict of interest to declare regarding this publication B. Hofauer: has participated as an investigator in clinical trials for CSL Behring and Takeda. H. Heppt: has no conflict of interest to declare regarding this publication E. Ebert: has received grant research support and/or speaker/consultancy fees from CSL Behring and Takeda. She has also received funding to attend conferences/educational events from CSL Behring, Takeda and Pharming. She has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, IONIS Pharmaceuticals and Takeda. J. Hahn: has received speaker/consultancy fees from CSL Behring and Takeda. She has also received funding to attend conferences/educational events from CSL Behring and Takeda. She has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, Pharvaris and Takeda. J. Greve: has received speaker/consultancy fees from CSL Behring, Takeda, Kalvista and BioCryst. He has also received funding to attend conferences/educational events from CSL Behring and Takeda. He has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst and Takeda. B. Wollenberg: has no conflict of interest to declare regarding this publication R. Lochbaum: Robin Lochbaum has received consultancy fees from BioCryst and Takeda. He has also received funding to attend conferences/educational events from CSL Behring, BioCryst and Takeda. He has participated as an investigator in a clinical trial/registry for Takeda and Pharvaris. S. Trainotti: has received grant research support and/or speaker/consultancy fees from CSL Behring and Takeda. She has also received funding to attend conferences/educational events from CSL Behring and Takeda. She has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, IONIS Pharmaceuticals and Takeda.
: This study complies with internationally accepted standards for research practice and reporting and was approved from the ethics board of the Technical University of Munich and Ulm University.The manuscript is not under simultaneous consideration with another journal, and has not been published before, and all authors concur with the submission.